1.
Respir Med Case Rep
; 22: 7-10, 2017.
Article
in English
| MEDLINE
| ID: mdl-28761805
ABSTRACT
Targeted therapies are on the market for the past five years and recently pembrolizumab was approved as first line treatment for patients with PD-L1 >50%. We present three cases of patients which had epidermal growth factor receptor positive expression and programmed death-ligand 1 (PD-L1), PD-L1 >50% overexpression.